Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 8/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862496 | 0.89 | PTGES (0.41) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL3863828 | 0.86 | PTGES (0.39) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL3863821 | 0.86 | PTGES (0.39) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL30074835 | 0.84 | PTGES (0.44) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL20475933 | 0.84 | PTGES (0.44) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL1043132 | 0.83 | MEN1 (0.41) | EGFRMAPTALDH1A1 | |
| SCHEMBL6106000 | 0.81 | PTGES (0.36) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL6106006 | 0.81 | PTGES (0.36) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL1490815 | 0.81 | MAPT (0.44) | PTGESEGFRFBP1MAPTALDH1A1 | |
| SCHEMBL204085 | 0.81 | KAT2B (0.43) | PTGESEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | PTGES 296/4885EGFR 3216/4885FBP1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.